Previous studies have demonstrated that non-invasive liver fibrosis scores (LFSs) are associated with kidney function deterioration. This study aimed to assess the predictive performance of LFSs in contrast-associated acute kidney injury (CA-AKI) in coronary artery disease (CAD) patients undergoing elective percutaneous coronary intervention (PCI). This retrospective study involved 5627 patients. The frequency of CA-AKI was 6.3% (n = 353). In a multivariate logistic analysis after adjustment, non-invasive LFSs, including fibrosis-5 score (FIB-5), fibrosis-4 score (FIB-4), aspartate aminotransferase to alanine aminotransferase ratio (AAR), and aspartate aminotransferase to platelet ratio index were independent risk factors for CA-AKI (all P < .05), whereas the Forns score was not (P > .05). The highest predictive performance was observed for FIB-5 (area under the curve [AUC] = .644) compared to other LFSs. A restricted cubic spline analysis confirmed approximately linear relationships between LFSs and risks of CA-AKI. Furthermore, adding FIB-5 (AUC = .747; net reclassification improvement [NRI] = .441, P < .001; integrated discrimination improvement [IDI] = .008, P < .001) or AAR (AUC = .747; NRI = .419, P < .001; IDI = .006, P = .010) to an established clinical risk model could significantly improve the prediction of CA-AKI. The LFSs were significantly associated with CA-AKI, possibly serving as predictive tools for early identification of CAD patients undergoing elective PCI that are at high risk of CA-AKI.
InoharaTNumasawaYHigashiT, et al.Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications. Am Heart J. 2017;194:61-72.
2.
WeisbordSDPalevskyPMKaufmanJS, et al.Contrast-associated acute kidney injury and serious adverse outcomes following angiography. J Am Coll Cardiol. 2020;75:1311-1320.
3.
KurogiKIshiiMSakamotoK, et al.Persistent renal dysfunction in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. J Am Heart Assoc. 2019;8:e014096.
4.
NarulaAMehranRWeiszG, et al.Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35:1533-1540.
5.
YounossiZMKoenigABAbdelatifDFazelYHenryLWymerM. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
6.
ZhouFZhouJWangW, et al.Unexpected rapid Increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology. 2019;70:1119-1133.
7.
WongVWWongGLYeungJC, et al.Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology. 2016;63:754-763.
8.
CohenJCHortonJDHobbsHH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523.
9.
EkstedtMHagströmHNasrPFredriksonMStålPKechagiasSHultcrantzR. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547-1554.
10.
HensonJBSimonTGKaplanAOsganianSMasiaRCoreyKE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51:728-736.
11.
CardosoCVillela-NogueiraCALeiteNCSallesGF. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort study. Cardiovasc Diabetol. 2021;20:193.
12.
OstovanehMRAmbale-VenkateshBFujiT, et al.Association of liver fibrosis with cardiovascular diseases in the general population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging. 2018;11:e007241.
13.
JungCYRyuGWKimHWAhnSHKimSUKimBS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia. 2022;65:518-527.
14.
CiardulloSBallabeniCTrevisanRPerseghinG. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: A systematic review and meta-analysis. Biomolecules. 2022;12, 105.
15.
ImajoKKessokuTHondaY, et al.Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626-637.
16.
McPhersonSStewartSFHendersonEBurtADDayCP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265-1269.
17.
LeroyVHilleretMNSturmN, et al.Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-782.
18.
LacknerCStruberGLieglB, et al.Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376-1382.
19.
KangSHLeeHWYooJJ, et al.KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27:363-401.
20.
ChalasaniNYounossiZLavineJE, et al.The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609.
21.
KimDKimWRKimHJTherneauTM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-1365.
22.
Vieira BarbosaJMilliganSFrickA, et al.Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117:453-461.
23.
MehtaRLKellumJAShahSV, et al.Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
24.
AttallahAMShihaGEOmranMMZalataKR. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res. 2006;34:163-169.
25.
SterlingRKLissenEClumeckN, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
26.
ShethSGFlammSLGordonFDChopraS. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44-48.
27.
FornsXAmpurdanèsSLlovetJM, et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-992.
28.
WaiCTGreensonJKFontanaRJKalbfleischJDMarreroJAConjeevaramHSLokAS-F. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
29.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
30.
XuHWHsuYCChangCHWeiKLLinCL. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int. 2016;10:340-346.
31.
WijarnpreechaKThongprayoonCScribaniMUngprasertPCheungpasitpornW. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. Eur J Gastroenterol Hepatol. 2018;30:404-410.
32.
SchonmannYYeshuaHBentovIZelber-SagiS. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79-85.
33.
ChenQLiQLiD, et al.Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis. 2020;299:45-52.
34.
LiuHHCaoYXJinJL, et al.Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention. J Am Heart Assoc. 2021;10:e018869.
35.
ShiYYZhengRCaiJJFangZ-DChenW-JPanJ-YQianS-Z. Association of FIB-4 index and clinical outcomes in critically ill patients with acute kidney injury: A cohort study. BMC Gastroenterol. 2021;21:483.
36.
Campos-MurguíaARomán-CallejaBMToledo-CoronadoIV, et al.Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis. 2021;53:525-533.
37.
MehranRAymongEDNikolskyE, et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
38.
ÇınarTTanıkVOAruğaslanEKarabağYÇağdaşMRencüzoğullarıIKeskinM. The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovasc Interv Ther. 2019;34:207-215.
39.
ÇınarTKarabağYOzan TanıkVÇağdaşMRencüzoğullarıİÖzA. The investigation of TIMI risk index for prediction of contrast-induced acute kidney injury in patients with ST elevation myocardial infarction. Acta Cardiol. 2020;75:77-84.
40.
ShihaGSeifSEldesokyA, et al.A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int. 2017;11:286-291.
41.
KwonHCSongJJParkYBLeeSW. Fibrosis-5 predicts end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis without substantial liver diseases. Clin Exp Med. 2021;21:399-406.
42.
EsenboğaKKurtulANazmanH, et al.Evaluation of the impact of ranolazine treatment on liver function tests in patients with coronary heart disease and nonalcoholic fatty liver disease. Angiology. 2022;73:73-78.
43.
TargherGDayCPBonoraE. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
44.
MamoulakisCTsarouhasKFragkiadoulakiI, et al.Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017;180:99-112.
45.
KusirisinPChattipakornSCChattipakornN. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med. 2020;18:400.
46.
SimsekBCinarTInanD, et al.C-Reactive protein/albumin ratio predicts acute kidney injury in patients with moderate to severe chronic kidney disease and non-ST-segment elevation myocardial infarction. Angiology. 2022;73:132-138.
47.
SimonettoDAGinesPKamathPS. Hepatorenal syndrome: Pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
